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Abstract
Background: Individuals with precapillary pulmonary hypertension (PH) experience severely impaired quality of life.
A disease-specific outcome measure for PH, the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)
was developed and validated in the UK and subsequently adapted for use in additional countries. The aim of this
study was to translate and assess the reliability and validity of the CAMPHOR for German-speaking populations.
Methods: Three main adaptation stages involved; translation (employing bilingual and lay panels), cognitive
debriefing interviews with patients and validation (assessment of the adaptation’s psychometric properties). The
psychometric evaluation included 107 patients with precapillary PH (60 females; age mean (standard deviation)
60 (15) years) from 3 centres in Austria, Germany and Switzerland.
Results: No major problems were found with the translation process with most items easily rendered into
acceptable German. Participants in the cognitive debriefing interviews found the questionnaires relevant,
comprehensive and easy to complete. Psychometric analyses showed that the adaptation was successful. The three
CAMPHOR scales (symptoms, activity limitations and quality of life) had excellent test-retest reliability correlations
(Symptoms = 0.91; Activity limitations = 0.91; QoL = 0.90) and internal consistency (Symptoms = 0.94; Activity
limitations = 0.93; QoL = 0.94). Predicted correlations with the Nottingham Health Profile provided evidence of the
construct validity of the CAMPHOR scales. The CAMPHOR adaptation also showed known group validity in its ability
to distinguish between participants based on perceived general health, perceived disease severity, oxygen use and
NYHA classification.
Conclusions: The CAMPHOR has been shown to be valid and reliable in the German population and is
recommend for use in clinical practice.
Keywords: Pulmonary hypertension, Pulmonary arterial hypertension, Chronic thromboembolic pulmonary
hypertension, Quality of life, Patient reported outcome, German adaptation
Introduction
Precapillary pulmonary hypertension (PH) consists of
the WHO clinical classes 1 and 4, i.e. pulmonary arterial
hypertension (PAH) and chronic thromboembolic PH
(CTEPH). Despite many new therapeutic options (with
the exception of patients with operable CTEPH) life ex-
pectancy is still dramatically shortened [1-3]. Hence, the
search for new therapies is on-going, and multiple trials
are underway or being planned. One of the main pro-
blems of planning such large trials is the absence of an
ideal endpoint [4]. Invasive haemodynamic parameters
are considered to represent hard endpoints, which are
optimal for phase II trials. However, it is not feasible to
perform these measurements repeatedly in everyday
clinical practice. Most trials now rely on the 6-minute
walking distance (6MWD) as the primary endpoint.
However, this test has many flaws including disagree-
ment about the normal values, the quality with which it
is conducted, high standard deviation of distances walked
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and large minimally important difference of over 40
meters [5]. In reality, exercise testing does not provide an
accurate reflection of how patients really feel.
As a consequence, quality of life (QoL) has emerged as
a potentially important endpoint. Most clinical studies to
date have used generic patient-reported outcome mea-
sures such as the SF-36 [6-9], the EuroQol [9,10] or the
Nottingham Health Profile [11]. However, generic instru-
ments generally have a low responsiveness, particularly
with PH patients [12]. For instance, the minimally im-
portant difference of the SF-36 domains range between
13 and 25 points on a 100-point scale [12]. This implies
that scores have to improve by up to 25 points before the
change is noticeable by patients. Some trials have applied
a modified version of the Minnesota Living with Heart
Failure (MLWHF) questionnaire [13,14]. Although this
has been shown to have a reasonable performance
[15,16] it was not designed for patients with PH.
Given the impact of PH on morbidity, comprehensive
disease-specific measures that directly address PH char-
acteristics are needed. The Cambridge Pulmonary Hy-
pertension Outcome Review (CAMPHOR) was designed
as a disease-specific measure to assess both health-
related QoL (symptoms and activity limitations) and
QoL in patients diagnosed with PH [17]. It is an evalu-
ation tool designed for use in clinical trials and clinical
practice. The present paper describes the translation and
validation of the CAMPHOR for use in German speak-
ing countries. A successful adaptation will provide a
valid and reliable outcome measure for use in PH clin-
ical practice and clinical trials at German speaking
centres.
Methods
The adaptation of the CAMPHOR questionnaire was con-
ducted in the three German-speaking countries; Austria,
Germany and Switzerland. The process consisted of three
main stages; translation (by means of bilingual and lay
panels), cognitive debriefing interviews with patients to
determine face and content validity and validation by
means of a clinic visit and postal survey. Ethics committee
approval was obtained from each participating centre
and written informed consent was obtained from all
participants.
Step 1: Translation process
The bilingual translation panel involved a group of 2
Austrian, 3 German and 4 Swiss participants (7 females
and 2 males with a median age of 47 and a range of 30
to 62 years) with good competence in both English and
German who had the latter as their primary language.
They were asked to consider the UK CAMPHOR
instructions and items with the following requirements
in mind; capturing the same concepts as the UK English
version and producing a comprehensible and acceptable
formulation of the concepts. Each item was discussed
until agreement was reached. Where consensus could
not be reached alternative versions of the item were
taken forward for consideration by the lay panel.
A separate lay translation panel consisted of 1 Austrian,
2 German and 3 Swiss non-bilingual participants (3
females and 3 males; median age 27 ranging from 18 to
76 years). The purpose of this second panel was to ensure
that the wording of items was appropriate for future
respondents with average educational achievement. Parti-
cipants were presented with the translations made by the
bilingual panel and asked to comment on these in terms
of comprehension and acceptability. In particular, they
were asked to decide whether phrasing and language were
acceptable or whether these should be changed to make
the items more ‘natural’ while maintaining their original
meaning. Where necessary they were also asked to choose
between alternative translations that the bilingual panel
had produced.
Step 2: Cognitive debriefing interviews
Cognitive debriefing interviews were conducted with 4
PH patients from each country (Table 1). Eight of the
interviewees had idiopathic pulmonary arterial hyperten-
sion (IPAH), 3 chronic thromboembolic pulmonary
hypertension (CTEPH) and 1 had PH associated with
scleroderma. The purpose of these interviews was to test
the applicability, comprehension, relevance and compre-
hensiveness of the new scales with relevant patients. In
the interviews, which were conducted face-to-face and
semi-structured, the respondents were asked to com-
plete the questionnaire in the presence of an interviewer
and then to answer specific questions about the meas-
ure. Respondents were also asked whether any aspects
of their experience of PH had been omitted.
Step 3: Validation
To validate the German version of the CAMPHOR, 107
PH patients from the three participating centres were
recruited (Tables 1 and 2). During a visit to the out-
patient clinic questions about demography (sex, age,
marital status, occupation) and current condition (time
since diagnosis, duration of symptoms, oxygen use and
perceived general health) were asked. During the visit a
6MWT also was performed according to current guide-
lines [18]. This measures the distance a patient can walk
quickly on a flat, hard surface in 6 minutes. It is
intended to indicate functional capacity. Its reliability
has been shown to be good in a number of different dis-
eases [19-21]. The measure has also been shown to cor-
relate with a number of PH related outcomes [22,23].
NYHA functional class was determined at the out-
patient visit (Class 1, no functional limitation; Class 2,
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slight functional limitation; Class 3, marked functional
limitation; Class 4, inability to perform functions without
symptoms) [24].
Patients also completed the Nottingham Health Profile
(NHP; [25]).
The CAMPHOR was then administered on two occa-
sions by mail approximately two weeks apart.
Statistical analyses
Data are presented as means and standard deviations
(SD) for illustrative purposes. Non-parametric statistical
tests were used throughout the analyses due to the or-
dinal nature of the measures employed. All statistical
tests were two-tailed with a P value of < .05 indicating
statistical significance. Internal consistency of the CAM-
PHOR adaptations was evaluated by determining Cron-
bach’s alpha coefficients. The relatedness of individual
items to the overall score was also assessed using the
corrected item-total correlation coefficients. Test-retest
reliability (patient-specific agreement between the two
repeated administrations) was examined using Spear-
man’s rank correlations. Construct validity was assessed
with the NHP as the comparator instrument.
Known-group validity (ability to distinguish between
groups of patients who differed according to some
known factor) was tested for:
– Perceived general health (very good/good; fair; poor/
very poor)
– Perceived PH severity (No symptoms/mild;
Moderate; Quite severe/very severe)
Table 2 Validation sample; disease information (n = 107)
Cause of PH
Idiopathic PAH (%) 47 (45.2)
Associated PAH (%) 24 (21.2)
CTEPH (%) 36 (33.6)
Missing 0
Duration of PH (years)
Mean (SD) 4.0 (4.5)
Range 0.2–25.0
Missing 6
Hospital admission in last year due to PH
Yes (%) 4 (3.8)
No (%) 101 (96.2)
Missing 2
Oxygen
Yes (%) 40 (37.7)
No (%) 66 (62.3)
Missing 1
NYHA Classification
I (%) 3 (2.8)
II (%) 42 (39.3)
III (%) 56 (52.3)
IV (%) 6 (5.6)
Missing 0
6 Min Walk Test (metres)
Mean (SD) 447.9 (112.7)
Range 180–660
Missing 8
Perceived general health
Very good/Good (%) 65 (62.5)
Fair (%) 28 (26.9)
Very poor/ Poor (%) 11(10.6)
Missing 3
Perceived severity of PH
No symptoms (%) 2 (1.9)
Mild (%) 23 (22.3)
Moderate (%) 55 (53.4)
Very & Quite severe (%) 23 (22.3)
Missing 12
Table 1 Demographic information
Cognitive debriefing
interview panel
(n = 12)
Validation sample
(n = 107)
Gender
Male (%) 3 (25.0) 46 (43.4)
Female (%) 9 (75.0) 60 (56.6)
Missing 0 1
Age (years)
Mean (SD) 60.2 (17.9) 60.3 (15.1)
Range 22 − 80 22–88
Missing 0 0
Nationality
Swiss (%) 4 (33.3) 39 (36.4)
Austrian (%) 4 (33.3) 34 (31.8)
German (%) 4 (33.3) 34 (31.8)
Missing 0 0
Marital status
Married/living as married (%) 7 (58.3) 68 (64.2)
Living alone (%) 5 (41.7) 38 (35.8)
Missing 0 1
Employment status
Working (%) 3 (25.0) 21 (19.8)
Not working (%) 9 (75.0) 85 (80.2)
Missing 0 1
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– Oxygen use (yes / no)
– NYHA class (NYHA I and II versus NYHA III and
IV)
Outcome measures
CAMPHOR
The CAMPHOR was originally developed and validated
in the United Kingdom [17]. It has subsequently been
adapted for use in the US [26], Canada (French and
English) [27], Australia / New Zealand [28] and Sweden.
It consists of a 25-item symptoms scale (scored 0–25), a
15-item functioning scale (scored 0–30) and a 25-item
QoL scale (scored 0–25). For all scales, a low score indi-
cates a better status. All language versions have been
shown to have good internal consistency, reproducibility
and validity [26-28].
Nottingham Health Profile
The NHP is a 38-item measure of perceived distress that
has been widely used in health research [25]. It consists
of six sections that assess; energy level, pain, emotional
reactions, sleep, social isolation and physical mobility.
All sections are scored 0 to 100 with a low score indicat-
ing good health status.
The NHPD is a 24-item unidimensional scale of im-
pairment embedded in the NHP [29].
Results
Translation
No major difficulties were experienced during the trans-
lation process and most items in the questionnaire were
translated without difficulty. Agreement was generally
reached with little panel discussion. However, a small
number of phrases required more extensive discussion.
For example, “glücklich” was chosen instead of “zufrie-
den” for “happy” since the latter was considered to be
closer to “satisfied” than “happy”. “Mein Zustand belastet
mich” was preferred to “Mein Zustand nimmt mich mit”
for “It gets me down” because the former was thought
to represent the burden of the disease better. “Zur Zeit”
was favoured over “zum jetzigen Zeitpunkt” for “at the
moment”, as the latter was believed to be more accurate.
Cognitive debriefing interviews
The CAMPHOR was completed in a median of 15
(range 7 to 25) minutes. Based on their responses parti-
cipants found the questionnaire to be clear, unambigu-
ous, comprehensive and easy to complete. Only minor
difficulties were reported. For example, one patient had
difficulty understanding one of the items and another
thought that a different item was not relevant. None of
the patients judged the questionnaire to be inappropriate
or difficult to answer. Three patients thought that an
additional item should be added to the questionnaire.
Each suggested a different item and none were relevant
to the content of the scales. No changes were required
to the questionnaire as a result of the cognitive debrief-
ing interviews. However, despite the instructions, only
two respondents checked that they had answered all
questions after completing the measure. Consequently,
the instructions were highlighted in an attempt to over-
come this oversight.
Validation
One-hundred and seven participants were recruited at
Time 1. At Time 2, 97 of these (90.7%) completed and
returned the questionnaires.
Sample demographics
Participant details are shown in Table 1. Individual
country sample sizes were insufficient to permit assess-
ment of the national psychometric properties separately
and the samples were merged for the analysis. Disease
information for the sample is shown in Table 2.
Questionnaire descriptive scores
The missing response rate at the item level on both the
CAMPHOR and NHP varied between 2 and 3%.
CAMPHOR scores at Time 1 are shown in Table 3.
The scores for the CAMPHOR were relatively low sug-
gesting that the sample had relatively mild PH. Floor
effects (>10% of patients scoring minimum) were evident
for the QoL scale. This reflects the mild nature of the
sample.
Internal consistency and reproducibility
Internal consistency and test-retest reliability (reproduci-
bility) are shown in Table 4. Reproducibility was above
the required 0.85 level for all three scales. Internal
consistency (Cronbach’s alpha) coefficients for the three
scales were above the minimum required 0.7 indicating
adequate inter-relatedness of items in each scale. The
coefficients were above 0.9 for all CAMPHOR scales
suggesting possible redundancy of items. The corrected
item-total correlation coefficients (CITCC) were exam-
ined for all three scales to determine if there were any
redundant items (items outside the 0.2 – 0.8 range).
None of the items had CITCC’s above 0.8. In addition,
the deletion of any one item would not have decreased
the Cronbach’s alpha value significantly.
Convergent validity
Table 5 shows correlations between the CAMPHOR,
NHP and the 6MWT at Time 1. The symptoms scale
showed strongest correlations with the emotional reac-
tions, energy level and physical mobility sections of the
NHP. It is known that PH has a close relation to these
outcomes. The activity limitations scale most closely
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related to physical mobility and energy level. Again this
would be expected as the activity limitations scale
assesses physical mobility and energy level is also closely
related to mobility. For the same reason the 6MWT had
the highest correlation with the activity limitations scale
of the CAMPHOR. QoL was clearly influenced by all
issues covered by the NHP but less so by pain and social
isolation.
Association of CAMPHOR scores with demographic
factors
There were no significant differences in mean CAM-
PHOR scores related to gender with the exception of the
Activity limitations scale where females scored higher
than males (means = 9.3 and 7.8 respectively, p < .05).
Older individuals (above median age) scored higher on
the Symptoms scale than younger respondents (means =
5.9 and 9.1 respectively, p < .05) and Activity limitations
scale (means = 6.7 and 10.9 respectively, p < 0.001). There
were no differences in CAMPHOR scale scores related
to duration of PH.
Known group validity
Known groups validity results are shown in Table 6. All
three CAMPHOR scales were able to discriminate be-
tween patients based on their perceived general health
and severity of PH. Individuals with worse general health
and worse PH had higher scores for the Symptoms, Ac-
tivity limitations and QoL scales. All three CAMPHOR
scales were able to distinguish between participants
based on whether or not participants received oxygen
for their PH.
Figure 1 shows CAMPHOR scores by NYHA classifi-
cation. The figure shows that the CAMPHOR was able
to discriminate well between patients. Due to the small
number of patients in classes I and IV statistical analyses
compared respondents in NYHA groups I and II com-
bined with participants in groups III and IV combined.
Individuals in groups NHYA III & IV had higher CAM-
PHOR scores than those in NHYA I and II (Symptoms
p < .001; Activity limitations p < .001; QoL p < .05).
Discussion
The results showed that the adaptation of the CAM-
PHOR for use with German speaking participants was
successful. Few problems were encountered during the
translation process. All participants in the cognitive
debriefing panel reported that the measure was easy to
complete and that it covered important aspects of their
experience of PH.
All scales in the CAMPHOR had good internal
consistency and reproducibility. The CAMPHOR
showed expected levels of association with the different
Table 3 Questionnaire descriptive scores Time 1 (n =107)
Mean (SD) Median IQR Range % scoring minimum % scoring maximum
CAMPHOR
Symptoms 7.4 (6.5) 5.5 2–13 0–25 8.4 0.9
Activity limitations 8.7 (6.3) 8.0 3–13 0–29 6.5 0
QoL 5.1 (6.0) 3.0 1–7 0–24 21.5 0
NHP
Energy level 38.6 (38.3) 33.3 0–66.7 0–100 37.4 18.7
Pain 10.6 (19.8) 0.0 0–12.5 0–100 60.7 0.9
Emotional reactions 13.0 (18.1) 0.0 0–22.2 0–78 48.6 0
Sleep 24.5 (29.1) 20.0 0–40 0–100 42.1 2.8
Social isolation 5.2 (13.7) 0.0 0 0–80 80.4 0
Physical mobility 22.3 (21.0) 12.5 0–37.5 0–100 29.0 0.9
NHPD 3.4 (3.6) 2.0 0–6 0–14 28.0 0
Table 4 Internal consistency and reproducibility of the
CAMPHOR scales adaptations (n = 107)
Symptoms Activity limitations QoL
Internal consistency .94 .93 .94
Test-retest reliability .91 .91 .90
Table 5 Convergent validity CAMPHOR scales and NHP
sections (n = 107)
Symptoms Activity limitations QoL
NHP-Energy level .82 .66 .71
NHP-Pain .45 .56 .54
NHP-Emotional reactions .74 .59 .72
NHP-Sleep .50 .39 .51
NHP-Social isolation .39 .32 .38
NHP-Physical mobility .74 .76 .70
NHP-D .81 .66 .72
6 Minute Walk Test (meters) -.43 -.56 -.41
All correlations were significant at p < .01.
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NHP sections. Further evidence of the validity of the
German CAMPHOR was shown by its ability to dis-
tinguish between groups known to differ by perceived
disease severity, general health and oxygen use. Import-
antly, clinical validity was also demonstrated; CAM-
PHOR scores were moderately related to the 6MWT
and were able to distinguish between NYHA classifica-
tions. On the basis of these findings clinicians working
in the three German-speaking nations can have confi-
dence in CAMPHOR scale scores.
One of the strengths of the study is that it tested
the CAMPHOR in 3 German-speaking countries. In
all these countries written German is the same mod-
ern Standard German known as High German
(Hochdeutsch). Most non-German researchers may
not consider the differences between the German speaking
nationalities and assume that an adaptation in one country
will be suitable for all German speakers. However, the lan-
guage used in the CAMPHOR is, intentionally, as informal
as possible and it is possible that this could have led to dif-
ferences in wording in the different countries. Variations
between the German dialects are considerable and often
only the neighbouring dialects are mutually intelligible.
Low German, most Upper German and even some Central
German dialects when spoken in their purest form are not
intelligible to people who only know standard German.
The German dialects of South Tyrol have been influenced
by local Romance languages with many words borrowed
from Italian. Furthermore, there is no standard Swiss
German. Valais German differs markedly from Bernese
German. Hence, adapting the CAMPHOR in relatively
central cities in the three countries should guarantee a
broad understandability.
The sample included in this study appeared to be less
severe than those commonly included in clinical trials
and in the UK validation survey. However, this study was
designed to test the performance of the German CAM-
PHOR rather than to report on the impact of PH on
QoL. Future studies can be undertaken to relate PH
variables to QoL.
Increasingly, health authorities are conducting eco-
nomic evaluations in health care. High-cost orphan dis-
eases like PH are prone to careful scrutinisation. The
preferred methodology is cost utility analysis (CUA)
whereby the benefits of health care interventions are
measured according to quality adjusted life years
(QALYs). Due to their lack of sensitivity and relevance,
the commonly used generic preference based measures
of health status may be inappropriate for some specific
Table 6 CAMPHOR scale scores by disease factors (n =100-102)
Symptoms Activity limitations QoL
n Mean (SD) n Mean (SD) n Mean (SD)
Perceived general health
Very good/good 64 4.4 (4.3) 63 6.1 (5.2) 64 2.7 (3.8)
Fair 26 10.7 (5.8) 28 10.9 (5.3) 25 7.6 (6.8)
Poor/very poor 11 17.6 (3.5) 11 17.1 (4.9) 11 13.3 (5.3)
p <.001 <.001 <.001
Perceived severity of PH
No symptoms / mild 25 3.7 (3.4) 25 5.3 (4.3) 25 2.3 (2.7)
Moderate 53 5.9 (5.4) 54 7.4 (5.5) 53 3.9 (5.4)
Quite / very severe 23 15.2 (4.6) 23 15.1 (5.3) 22 11.1 (6.1)
p <.001 <.001 <.001
Oxygen use
Yes 38 9.8 (6.8) 37 11.6 (6.7) 37 7.3 (6.5)
No 63 5.9 (5.7) 65 7.0 (5.5) 63 3.6 (5.0)
p .003 <.001 .001
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Figure 1 Mean CAMPHOR scales scores by NHYA classifications.
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clinical conditions such as PH. The CAMPHOR Utility
Index embedded in the CAMPHOR QoL scale permits
derivation of PH-specific utility scores [30]. In contrast
to traditional outcomes, such as NYHA functional class,
6MWD and generic QoL instruments, it has been shown
to be valid and responsive to change [31]. Further stud-
ies testing the use of the CAMPHOR utility index with
German speaking PH patients would be beneficial.
In conclusion, the current study shows that the German
translation of the CAMPHOR is a valid and reliable in-
strument for assessment of health-related QoL and QoL
in patients with precapillary PH. Its use in clinical practice
can be recommended.
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